- Home
- ESEA vs RIGL Comparison
ESEA vs RIGL Comparison
Compare ESEA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESEA | RIGL |
|---|---|---|
| Founded | 2005 | 1996 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.0M | 564.7M |
| IPO Year | 2005 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ESEA | RIGL |
|---|---|---|
| Price | $69.80 | $39.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $62.00 | $45.67 |
| AVG Volume (30 Days) | 45.6K | ★ 386.8K |
| Earning Date | 06-17-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 0.44 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $1.74 | N/A |
| Revenue Next Year | $1.07 | $12.75 |
| P/E Ratio | ★ $3.39 | $92.23 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $48.89 | $19.43 |
| 52 Week High | $78.76 | $52.24 |
Technical Indicators
Market Signals| Indicator | ESEA | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 60.50 |
| Support Level | $63.64 | $40.05 |
| Resistance Level | $72.24 | $44.42 |
| Average True Range (ATR) | 2.29 | 1.89 |
| MACD | 0.17 | -0.35 |
| Stochastic Oscillator | 61.39 | 37.81 |
Price Performance
Historical ComparisonAbout ESEA Euroseas Ltd. (Marshall Islands)
Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.